Biphenyls as potent vitronectin receptor antagonists. Part 2: Biphenylalanine ureas

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 6, 2003, Pages 1071-1074

  Urbahns, Klaus ^a,c   Härter, Michael ^a   Vaupel, Andrea ^a   Albers, Markus ^a   Schmidt, Delf ^a   Brüggemeier, Ulf ^a   Stelte Ludwig, Beatrix ^a   Gerdes, Christoph ^a   Tsujishita, Hideki ^b  

^a BAYER AG   (Germany)

^b Research Center Kyoto   (Japan)

^c BAYER YAKUHIN LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 BROMOPHENYLALANINE; BIPHENYL DERIVATIVE; FUNCTIONAL GROUP; PHENYLALANINE DERIVATIVE; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; UREA DERIVATIVE; VITRONECTIN RECEPTOR ANTAGONIST;

ARTICLE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

EID: 0037463755     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00023-4     Document Type: Article

References (20)

1. (a) Recent reviews: Samanen J., Jonak Z., Rieman D., Yue T.L. Current Pharm. Des. 3:1997;545.
2. (b) Miller W.H., Keenan R.M., Willette R.N., Lark M.W. Drug Discov. Today. 5:2000;397.
3. (c) Duggan M.E., Hutchinson J.H. Exp. Op. Ther. Pat. 10:2000;1367.
4. (d) Hoelzemann G. Idrugs. 40:2001;72.
5. Urbahns K., Härter M., Albers M., Schmidt D., Stelte-Ludwig B., Brüggemeier U., Vaupel A., Gerdes C. Bioorg. Med. Chem. Lett. 12:2002;205.
6. All compounds synthesized on Wang resin (Rapp Polymere, Tübingen, loading: 1.08 mmol/g) were obtained in good yields (50-80%). The purity was >90% as determined by HPLC (UV) in all cases. For further details of the syntheses see: Urbahns K., Härter M., Albers M., Vaupel A., Schmidt D., Stelte-Ludwig B., Gerdes C., Lustig K. WO 0035864, 2000, Chem. Abstr. 133:2000;43809.
7. 3 and related integrins. Hartman G.D., Egbertson M.S., Halczenko W., Laswell W., Duggan M.E., Smith R.L., Naylor A.M., Manno P.D., Lynch R.J., Zhang G., Chang C.T.-C., Gould R. J. Med. Chem. 35:1992;4640.
8. Baldwin J.E., Spivey A.C., Schofield C.J., Sweeney J.B. Tetrahedron. 49:1993;6309.
9. Experimental details in: Vaupel A. US 2002095050, 2002; Chem. Abstr. 137:2002;94007.
10. The 2,4,6-trimethyl phenyl sulfonyl residue has been incorporated into vitronectin receptor antagonists before: Voss E.J., Jadhav P.K., Smallheer J.M., Batt D.G., Pitts W.J., Wityak J. WO 9637492, 1996; Chem. Abstr. 126:1997;89360.
11. (a) Incorporation of camphor residues into beta 3 integrin antagonists: Diefenbach B., Fittschen C., Gante J., Goodman S., Wiesner M., Rippmann F. DE 95-195548709; Chem. Abstr. 127:1997;95612.
12. (b) Brashear K.M., Cook J.J., Bednar B., Bednar R.A., Gould R.J., Halczenko W., Holahan M.A., Lynch R.J., Hartman G.D., Hutchinson J.H. Bioorg. Med. Chem. Lett. 21:1997;2793.
13. Greenspoon N., Hershkoviz R., Alon R., Varon D., Shenkman G., Marx G., Federman S., Kapustina G., Lider O. Biochemistry. 32:1993;1001.
14. Integrin purification: Wong A., Hwang S.M., McDevitt P., McNulty D., Stadel J.M., Johanson K. Mol. Pharm. 50:1996;529 (b) . Echistatin as radioligand: Kumar C.C., Nie H.M., Rogers C.P., Malkowski M., Maxwell E., Catino J.J., Armstrong L. J. Pharm. Exp. Ther. 283:1997;843.
15. Integrin purification: Wong A., Hwang S.M., McDevitt P., McNulty D., Stadel J.M., Johanson K. Mol. Pharm. 50:1996;529 (b) . Echistatin as radioligand: Kumar C.C., Nie H.M., Rogers C.P., Malkowski M., Maxwell E., Catino J.J., Armstrong L. J. Pharm. Exp. Ther. 283:1997;843.
16. Ullmann G.M., Hauswald M., Jensen A., Kostic N.M., Knapp E.W. Biochemistry. 36:1997;16187.
17. (a) Xiong J.P., Stehle T., Diefenbach B., Zhang R., Dunker R., Scott D.L., Joachimiak A., Goodman S.L., Aranout M.A. Science. 294:2001;339.
18. (b) Xiong J.P., Stehle T., Zhang R., Joachimiak A., Frech M., Goodman S.L., Aranout M.A. Science. 296:2002;151.
19. 2+ ions, the ion chelating amino acids as well as all distant residues (5 Å) were kept constant. The docking procedure was performed using SYBYL 6.8 (Tripos Inc., MO, USA).
20. A similar effect is known for c-RGDfV. Substitution of the glycine residue by L- or D-alanine leads to loss of activity: Haubner R., Gratias R., Diefenbach B., Goodman S.L., Jonczyk A., Kessler H. J. Am. Chem. Soc. 118:1996;7461.